Associate Professor of , USC School of Medicine
Radiology
Dr. Peter S. Conti, MD
|
|
Give Review
Peter Conti is an expert in the field of Radiology. He went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University has a rank of 18 in research and a 49 in primary care He received awards:"Top Doctors:LA Area" and "Top Doctors:Southern California". Doctor Peter S. Conti, MD is a published doctor. He has 99 papers published. The most current publication "Cysteinyl-leukotriene D4 induced IL-1 beta expression and release in rat vascular smooth muscle cells." Doctor Peter S. Conti, MD is registered with Medicare and accepts Medicare payments.
Publications
- Improved Metabolic Stability for (18)F PET Probes Rapidly Constructed via Tetrazine trans-Cyclooctene Ligation.
- One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
- Sodium (18)F-Fluoride PET/CT of Bone, Joint, and Other Disorders.
- MicroPET Imaging of CD13 Expression Using a (64)Cu-Labeled Dimeric NGR Peptide Based on Sarcophagine Cage.
- In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
- Design, Synthesis, and Validation of Axl-Targeted Monoclonal Antibody Probe for microPET Imaging in Human Lung Cancer Xenograft.
- Integrin α2β1 targeted GdVO4:Eu ultrathin nanosheet for multimodal PET/MR imaging.
- Efficient synthesis of fluorescent-PET probes based on [(18)F]BODIPY dye.
- Facile Preparation of a Thiol-Reactive 18F-Labeling Agent and Synthesis of 18F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
- Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide.
- A Hybrid Protein-Polymer Nanoworm Potentiates Apoptosis Better than a Monoclonal Antibody.
- Axl-Targeted Cancer Imaging with Humanized Antibody h173.
- Characterization and Evaluation of (64)Cu-Labeled A20FMDV2 Conjugates for Imaging the Integrin αvβ 6.
- Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET.
- Evaluation of (18)F-labeled BODIPY dye as potential PET agents for myocardial perfusion imaging.
- Cytoreductive Chemotherapy Improves the Biodistribution of Antibodies Directed against Tumor Necrosis in Murine Solid Tumor Models.
- Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth and Metastasis.
- Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer.
- RGD-based PET tracers for imaging receptor integrin αv β3 expression.
- PET Imaging of Colorectal and Breast Cancer by Targeting EphB4 Receptor with 64Cu-Labeled hAb47 and hAb131 Antibodies.
- Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs.
- Lewis Acid-Assisted Isotopic (18)F-(19)F Exchange in BODIPY Dyes: Facile Generation of Positron Emission Tomography/Fluorescence Dual Modality Agents for Tumor Imaging.
- Development and Evaluation of 18F-TTCO-Cys40-Exendin-4: A PET Probe for Imaging Transplanted Islets.
- "Kit like" (18)F labeling method for synthesis of RGD peptide-based PET probes.
- Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring.
- Synthesis and Evaluation of (64)Cu-Labeled Monomeric and Dimeric NGR Peptides for MicroPET Imaging of CD13 Receptor Expression.
- PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).
- Kinetic quantification of protein polymer nanoparticles using non-invasive imaging.
- Radioactive Smart Probe for Potential Corrected Matrix Metalloproteinase Imaging.
- Microwave-assisted one-pot radiosynthesis of 2'-deoxy-2'-18Ffluoro-5-methyl-1-β-d-arabinofuranosyluracil (18F-FMAU).
- Fasting enhances the response of glioma to chemo- and radiotherapy.
- Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells.
- β-adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, and inflammatory response after traumatic brain injury.
- Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer.
- The efficient synthesis and biological evaluation of novel bi-functionalized sarcophagine for (64)cu radiopharmaceuticals.
- Quantitative, Simultaneous PET/MRI for Intratumoral Imaging with an MRI-Compatible PET Scanner.
- Efficient Construction of PET/Fluorescence Probe Based on Sarcophagine Cage: An Opportunity to Integrate Diagnosis with Treatment.
- In Vivo Near-Infrared Fluorescence Imaging of Integrin ?2?1 in Prostate Cancer with Cell-Penetrating-Peptide-Conjugated DGEA Probe.
- Efficient Preparation and Biological Evaluation of a Novel Multivalency Bifunctional Chelator for (64) Cu Radiopharmaceuticals.
- Novel ?(2)?(1) Integrin-targeted Peptide Probes for Prostate Cancer Imaging.
- Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ₃ targeted PET tracer based on a cyclic RGD peptide.
- Evaluation of (64)Cu Labeled GX1: A Phage Display Peptide Probe for PET Imaging of Tumor Vasculature.
- Design, synthesis and validation of integrin α(2)β (1)-targeted probe for microPET imaging of prostate cancer.
- Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide.
- A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice.
- Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
- The sodium bicarbonate cotransporter (NBCe1) is essential for normal development of mouse dentition.
- In vivo effect of propranolol dose and timing on cerebral perfusion after traumatic brain injury.
- Controlling familywise error rate for matched subspace detection in dynamic FDG PET.
- Site qualification in multicenter clinical trials.
- SNM molecular imaging summit introduces clinical trials network.
- Lesion detection in dynamic FDG-PET using matched subspace detection.
- The in vivo effect of propranolol on cerebral perfusion and hypoxia after traumatic brain injury.
- New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Introduction.
- Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
- New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
- Biglycan overexpression on tooth enamel formation in transgenic mice.
- Molecular imaging: the future of modern medicine.
- Choline autoradiography of human prostate cancer xenograft: effect of castration.
- B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
- F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
- Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.
- Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT.
- [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
- 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroi...
- Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice.
- 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer.
- Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide.
- The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
- Glucose metabolism of human prostate cancer mouse xenografts.
- Integrin alpha v beta 3-targeted imaging of lung cancer.
- The future of radioimmunotherapy: a PET perspective.
- Synthesis and evaluation of 2'-deoxy-2'-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression.
- Virchow's node on F-18 FDG PET/CT.
- In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts.
- Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
- Musculoskeletal system.
- The reproductive tract.
- MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides.
- microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
- Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model.
- Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide.
- MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide.
- Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
- Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
- Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings.
- Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression.
- Evaluation of 2'-deoxy-2'-flouro-5-methyl-1-beta-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo.
- Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
- Development of PET Probes for Cancer Imaging.
- (64)Cu Labeled Sarcophagine Exendin-4 for MicroPET Imaging of Glucagon like Peptide-1 Receptor Expression.
- Development of multi-functional chelators based on sarcophagine cages.
- Radiolabeled Nanoparticles for Multimodality Tumor Imaging.
- Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy.
- Cysteinyl-leukotriene D4 induced IL-1 beta expression and release in rat vascular smooth muscle cells.
- Aluminum impairs rat neural cell mitochondria in vitro.
- Synthesis and pharmacology of 3-hydroxy-delta2-isoxazoline-cyclopentane analogues of glutamic acid.
Schools
Weill Cornell Medical College
Johns Hopkins Med Institute
Doctors Specialties
- Diagnostic Radiology
- Nuclear Medicine
- Radiology
Accepted Insurances
Awards
- Top Doctors:LA Area
- Top Doctors:Southern California
Education
-
Johns Hopkins University -
St Luke's-Roosevelt Hospital Center -
Weill Cornell Medical College of Cornell University
Hospital
-
Keck Hospital of USC
Helpful Reviews
Similar Doctors
|
|
Dr. Arlene M. Klink, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Krane, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerome L. Faversham, MD |
|
|
Dr. Benito P. Laddaran, MD |
|
|
Dr. Vicki W. Quan, DO |
|
|
Dr. Rinat Masamed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Sam, MD |
|
|
Dr. Shahram Bonyadlou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Darflinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James M. Halls, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meredith P. Lewis, MD |
|
|
Dr. Heidy M. Rodriguez Hernandez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sassan Senaati, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Conor P. Meehan, MB |
|
|
Dr. Sidney G. Friedman, MD
This Doctor is OpenDoctor Recommended.
|